Abstract: Semiconductor dies of a semiconductor die package are directly bonded, and a top metal region may be formed over the semiconductor dies. A plurality of conductive terminals may be formed over the top metal region. The conductive terminals are formed of copper (Cu) or another material that enables low-temperature deposition process techniques, such as electroplating, to be used to form the conductive terminal. In this way, the conductive terminals of the semiconductor die packages described herein may be formed at a relatively low temperature. This reduces the likelihood of thermal deformation of semiconductor dies in the semiconductor die packages. The reduced thermal deformation reduces the likelihood of warpage, breakage, and/or other types of damage to the semiconductor dies of the semiconductor die packages, which may increase performance and/or increase yield of semiconductor die packages.

Abstract: A switching regulator includes a power stage circuit and a controller circuit. The controller circuit includes a first amplification circuit, a second amplification circuit, a ramp signal generation circuit, and a comparator. The first amplification circuit generates an amplification signal according to a difference between a low-pass filtered signal and a feedback signal. The second amplification circuit generates an adjustment signal according to a difference between the feedback signal and a fast response signal. The comparator generates a pulse width modulation signal according to a difference between the amplification signal and a ramp signal to generate a switch control signal. The adjustment signal adaptively adjusts the amplification signal or the ramp signal. The low-pass filtered signal is related to a signal generated by filtering out higher frequency part of the reference signal, and the reference signal is related to a dynamic change of a target level of the output voltage.

Abstract: The present invention relates to a composition of subunit dengue vaccine comprising a fusion protein of conjugating or connecting delta C nonstructural protein 1 (NS1?C or truncated NS1?C) to at least one polypeptides of NS3c (or truncated NS3c) and/or consensus envelope protein domain III (cEDIII), thereby enhancing better protection against DENV challenge and alleviating associated pathological effects.

Abstract: A timing generator includes a first current source, a first switch, a second current source, a second switch, a third switch, a capacitor, a signal synthesizer, and a timing difference extractor. The first current source is for generating a first current according to the input voltage. The second current source is for generating a second current according to the input voltage. The first switch includes a control terminal for receiving a charging signal. The second switch includes a control terminal for receiving a timing difference signal. The third switch includes a control terminal for receiving a reset signal. The capacitor is coupled between a charging terminal and a ground terminal. The signal synthesizer is for generating a timing signal according to a charging voltage and a reference voltage. The timing difference extractor is for generating a timing difference signal according to the timing signal and a deformed timing signal.

Abstract: The present invention relates to isolated monoclonal antibodies (mAbs) and/or antigen-binding fragments thereof that specifically recognize indoxyl sulfate, a protein-bound uremic toxin, and uses of such isolated anti-IS mAbs and/or antigen-binding fragments thereof to create immunoassay methods applied in theragnosis of IS-related diseases.

Abstract: The present invention relates to a method of elevating prediction accuracy of grouping subjects with severe dengue infection. In the method, a non-structural protein 1 (NS1) and an endogenous anti-NS1 antibody of dengue virus in an ex vivo biological specimen are detected and crossly compared, leading in reduce of false negative rates of testing results, as well as elevating grouping accuracy of patients with severe dengue infection.

Abstract: A switching regulator includes a power stage circuit and a controller circuit. The controller circuit includes a first amplification circuit, a second amplification circuit, a ramp signal generation circuit, and a comparator. The first amplification circuit generates an amplification signal according to a difference between a low-pass filtered signal and a feedback signal. The second amplification circuit generates an adjustment signal according to a difference between the feedback signal and a fast response signal. The comparator generates a pulse width modulation signal according to a difference between the amplification signal and a ramp signal to generate a switch control signal. The adjustment signal adaptively adjusts the amplification signal or the ramp signal. The low-pass filtered signal is related to a signal generated by filtering out higher frequency part of the reference signal, and the reference signal is related to a dynamic change of a target level of the output voltage.

Abstract: A switching power conversion circuit includes a conversion capacitor, a capacitive power conversion circuit, an inductor, an inductive power conversion circuit and a switching control circuit. The capacitive power conversion circuit switches the conversion capacitor periodically according to a switching control signal generated by the switching control circuit, to generate a first intermediate voltage and a first proportional voltage in a promptly rising mode and to generate a second intermediate voltage and a second proportional voltage in a promptly falling mode. In the promptly rising mode, a rising slope of an inductor current is determined by a difference between a high level of the first proportional voltage and an output voltage. In the promptly falling mode, a falling slope of the inductor current is determined by a difference between a low level of the second proportional voltage and the output voltage.

Abstract: A switching power conversion circuit includes a conversion capacitor, a capacitive power conversion circuit, an inductor, an inductive power conversion circuit and a switching control circuit. The capacitive power conversion circuit includes plural switching devices for generating an intermediate voltage which is in a predetermined proportional relationship to the input voltage. The inductive power conversion circuit includes plural switching devices for converting the intermediate voltage to an output voltage. The plural switching devices of the capacitive power conversion circuit and the inductive power conversion circuit switch the conversion capacitor and the inductor periodically according to the duty ratio of the switching control signal generated by the switching control circuit. The capacitive power conversion circuit and the inductive power conversion circuit share one of the plural switching devices.

Abstract: A switching power conversion circuit includes a conversion capacitor, a capacitive power conversion circuit, an inductor, an inductive power conversion circuit and a switching control circuit. The capacitive power conversion circuit switches the conversion capacitor periodically according to a switching control signal generated by the switching control circuit, to generate a first intermediate voltage and a first proportional voltage in a promptly rising mode and to generate a second intermediate voltage and a second proportional voltage in a promptly falling mode. In the promptly rising mode, a rising slope of an inductor current is determined by a difference between a high level of the first proportional voltage and an output voltage. In the promptly falling mode, a falling slope of the inductor current is determined by a difference between a low level of the second proportional voltage and the output voltage.

Abstract: Disclosed herein is an anti-DENV antibody, a pharmaceutical composition comprising the same, and uses thereof. According to embodiments of the present disclosure, the anti-DENV antibody comprises a heavy chain variable region and a light chain variable region, in which the heavy chain variable region comprises amino acid sequences of SEQ ID NOs: 1-3, and the light chain variable region comprises amino acid sequences of SEQ ID NOs: 5-7.

Abstract: A switching power conversion circuit includes a conversion capacitor, a capacitive power conversion circuit, an inductor, an inductive power conversion circuit and a switching control circuit. The capacitive power conversion circuit includes plural switching devices for generating an intermediate voltage which is in a predetermined proportional relationship to the input voltage. The inductive power conversion circuit includes plural switching devices for converting the intermediate voltage to an output voltage. The plural switching devices of the capacitive power conversion circuit and the inductive power conversion circuit switch the conversion capacitor and the inductor periodically according to the duty ratio of the switching control signal generated by the switching control circuit. The capacitive power conversion circuit and the inductive power conversion circuit share one of the plural switching devices.

Abstract: A multi-level switching power converter includes a multi-level power stage circuit which converts an input power to an output power. The power stage circuit includes an inductor, a conversion capacitor and plural power switches. The controller circuit controls the multi-level power stage circuit and includes: a feedback pulse generator circuit which generates a trigger pulse; a first timer circuit and a second timer circuit which determine a first time period and a second time period respectively according to the trigger pulse; and an adjusting circuit which adjusts the first time period according to a difference between the voltage across the conversion capacitor and a reference voltage such that an average of the voltage across the conversion capacitor is substantially equal to a level of the reference voltage.

Abstract: The present invention relates to a composition of subunit dengue vaccine comprising a fusion protein of conjugating or connecting delta C nonstructural protein 1 (NS1?C or truncated NS1?C) to at least one polypeptides of NS3c (or truncated NS3c) and/or consensus envelope protein domain III (cEDIII), thereby enhancing better protection against DENV challenge and alleviating associated pathological effects.

Abstract: A multi-level switching power converter includes a multi-level power stage circuit which converts an input power to an output power. The power stage circuit includes an inductor, a conversion capacitor and plural power switches. The controller circuit controls the multi-level power stage circuit and includes: a feedback pulse generator circuit which generates a trigger pulse; a first timer circuit and a second timer circuit which determine a first time period and a second time period respectively according to the trigger pulse; and an adjusting circuit which adjusts the first time period according to a difference between the voltage across the conversion capacitor and a reference voltage such that an average of the voltage across the conversion capacitor is substantially equal to a level of the reference voltage.

Abstract: The present invention relates to isolated monoclonal antibodies (mAbs) and/or antigen-binding fragments thereof that specifically recognize indoxyl sulfate, a protein-bound uremic toxin, and uses of such isolated anti-IS mAbs and/or antigen-binding fragments thereof to create immunoassay methods applied in theragnosis of IS-related diseases.

Abstract: The present invention relates to isolated monoclonal antibodies (mAbs) and/or antigen-binding fragments thereof that specifically recognize indoxyl sulfate, a protein-bound uremic toxin, isolated polynucleotide segment encoding the isolated antibodies and/or antigen-binding fragments thereof, and uses of such isolated anti-IS mAbs and/or antigen-binding fragments thereof to create immunoassay methods, device compositions, and pharmaceutical compositions applied in theragnosis of IS-related diseases.

Abstract: A multi-level switching power converter includes a multi-level power stage circuit which converts an input power to an output power. The power stage circuit includes an inductor, a conversion capacitor and plural power switches. The controller circuit controls the multi-level power stage circuit and includes: a feedback pulse generator circuit which generates a trigger pulse; a first timer circuit and a second timer circuit which determine a first time period and a second time period respectively according to the trigger pulse; and an adjusting circuit which adjusts the first time period according to a difference between the voltage across the conversion capacitor and a reference voltage such that an average of the voltage across the conversion capacitor is substantially equal to a level of the reference voltage.

Abstract: A multi-level switching power converter includes a multi-level power stage circuit which converts an input power to an output power. The power stage circuit includes an inductor, a conversion capacitor and plural power switches. The controller circuit controls the multi-level power stage circuit and includes: a feedback pulse generator circuit which generates a trigger pulse; a first timer circuit and a second timer circuit which determine a first time period and a second time period respectively according to the trigger pulse; and an adjusting circuit which adjusts the first time period according to a difference between the voltage across the conversion capacitor and a reference voltage such that an average of the voltage across the conversion capacitor is substantially equal to a level of the reference voltage.

Abstract: Disclosed herein is an anti-DENV antibody, a pharmaceutical composition comprising the same, and uses thereof. According to embodiments of the present disclosure, the anti-DENV antibody comprises a heavy chain variable region and a light chain variable region, in which the heavy chain variable region comprises amino acid sequences of SEQ ID NOs: 1-3, and the light chain variable region comprises amino acid sequences of SEQ ID NOs: 5-7.